Our principal objective in this program is to characterise and validate diabesity drug targets, particularly novel targets identified in other workpackages, by studies of key factors in the regulation of white and brown adipose tissues. The focus of research in the first 18 months will be on analyses of known drug targets that are a focus of research in this project, particularly nuclear receptors (the transcription factor FOXC2, Rev-erb–a, and glucocorticoid receptors), the corticoid metabolism enzyme 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD-1), and uncoupling proteins (UCPs). Research will extend after this time to include novel transcription factors, receptors and ligands identified by Consortium members.